Real-World Data from Italy: Luspatercept Shows Promise in Transfusion-Dependent Beta-Thalassemia
Mostafa Faisal, associate professor of Adult Hematology and BMT, recently shared a post on use of Luspatercept on X:
”Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy – The American Journal of Hematology.”
Read the full article here.
Following the approval of the drug in the U.S. and Europe—based on the findings of the randomized, placebo-controlled phase III BELIEVE trial—there remained a need to generate robust real-world evidence on its effectiveness, safety, and tolerability in routine clinical settings.
To address this, the impact of luspatercept treatment in a cohort of 231 individuals with TDT was assessed.
Published in the American Journal of Hematology, this new study presents one of the largest real-world cohorts examining the use of the drug in patients with transfusion-dependent beta-thalassemia (TDT) across Italy.
To learn more on new scientific advances in hematology, read Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH